NewsRoom Articles - Page 110 of 218

TuesdayJul 26, 2022 9:00 am

Odyssey Health, Inc. (ODYY), Determined to Introduce the Market’s First FDA Approved Concussion Treatment Drug

PBS News Hour estimates that, for college students, concussions cost between $446 million and $1.5 billion annually, while for high school students the cost ranges from $5.4 billion to $19.2 billion Odyssey, through its flagship product, PRV-002, hopes to offer the first FDA-approved drug treatment for concussions Once approved, Odyssey is confident that PRV-w002 will bring relief to thousands of victims, reduce the cost of concussion treatment and allow victims to lead normal, healthy, and productive lives The company is currently scheduling a meeting with the FDA to present findings from the phase I trial, as it identifies phase II…

MondayJul 25, 2022 12:49 pm

Study Highlights Concerns on Police Involvement in Emergency Mental Health Transfers

The police don’t have a good reputation when it comes to dealing with individuals with mental health crises. Police encounters have repeatedly proven to be particularly dangerous for people with mental illness, with these encounters often ending in injury and failing to provide the involved individuals the mental help they need. Even so, a recent study has revealed that university health centers in the Ontario region still rely on law enforcement for emergency mental-health transfers. The study, whose findings were reported in the “Canadian Medical Association Journal,” shows that health practitioners often prefer to call the police, even though they…

MondayJul 25, 2022 11:15 am

Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study

Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage Laboratories Recent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug delivery SPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis Company recently announced positive results in subcutaneous delivery of novel liposomes vs. intravenous injection Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company that focuses on fusing traditional therapeutics with psychedelic research, recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage…

MondayJul 25, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study

Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine months The pivotal study was designed with four primary objectives Cybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, a Phase 1 N,N-DMT study that provides key data relating to the company’s proprietary CYB004 substance (https://ibn.fm/2Ab0T). Information from the study is expected to help the company accelerate by up to nine months its clinical development pathway of CYB004. “With the closing of this transaction…

FridayJul 22, 2022 12:14 pm

Researchers Have Found a New, Fatal Pediatric Subtype of Cancer

Liver cancer is quite rare in children and teens, accounting for only 1% to 2% of pediatric cancers. Even so, it affects around two to three million minors, usually in the first three years of their lives. For the past couple of decades, experts have classified pediatric liver cancers as either hepatocellular or hepatoblastoma carcinomas, with statistics showing that the survival rate for hepatoblastoma after five years is 75% to 80%. Pediatric pathologists have now revealed that there are certain liver cancers whose characteristics do not meet the criteria of the two established carcinoma models. These liver tumors are more…

FridayJul 22, 2022 9:00 am

Successful Early Testing of Concussion Therapy Drives Optimism for Odyssey Health, Inc. (ODYY) as Next-stage Trials are Readied

Medical technology innovator Odyssey Health Inc. is using clinical tests to establish the safety of a therapy designed to treat concussion injuries in its earliest moments The company is enthused by results from the early-stage testing and is preparing to design a Phase II/III trial that will target efficacy results in volunteer subjects, focusing particularly on members of the military Odyssey’s technology combines a synthetic medication with a specially designed application device that helps the medication cross the blood-brain barrier for immediate responsiveness following a mild traumatic brain injury (“mTBI”) Medication for concussion treatment remains an unmet need and Odyssey…

ThursdayJul 21, 2022 10:22 am

Loss of Y Chromosomes in Older Men Elevates Heart Disease Risk, Study Finds

A new study has found that older men losing the Y chromosome in their white blood cells as they age can heighten their risk of death from cardiovascular illnesses and cause severe heart problems. This genetic change, which is scientifically referred to as mosaic Loss of y or mLOY, impacts about 20% of men aged 60 and 40% of those aged 70 and above. The study was carried out by researchers at Sweden’s Uppsala University and the University of Virginia. It was led by Professor Kenneth Walsh of the School of Medicine at the University of Virginia and Associate Professor…

WednesdayJul 20, 2022 10:31 am

Study Reveals Proteins That Can Trigger Immune System Malfunction

At least 20 million Americans live with autoimmune disorders, but there’s still much we don’t know about these conditions. The disorders usually occur when, for some reason, the immune system goes haywire and begins to attack healthy tissue. In addition to not knowing exactly what causes autoimmune disorders, we still haven’t figured out a way to cure them. Recently, however, researchers studying immune disorders discovered a novel method of triggering the immune system via certain proteins. This discovery could provide scientists with the chance to know more about autoimmune conditions such as lupus and scleroderma. Investigators from Weill Cornell Medicine…

WednesdayJul 20, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Responds to Growing Concerns About Concussion Head Injuries with Drug Device in Clinical Trial

As awareness of the long-term hazards of concussive head injuries for young athletes has increased during the past decade, advocates and business enterprises have stepped up to improve coach responsiveness to players’ condition While efforts primarily focus on assessing injury, Odyssey Health Inc. is developing a product it hopes to become the first drug device with FDA approval for treating a concussed patient after injury Odyssey is enrolling patients in a Phase 1 human clinical trial after completing pre-clinical studies in laboratory animals The medical research company’s assets include treatments for patients who may have undiagnosed heart disease, patients choking…

TuesdayJul 19, 2022 12:46 pm

Study Highlights New Insights on Neurological Autoimmune Illnesses

UT Southwestern researchers recently reported that they had used cryoelectron microscopy to obtain the image of an auto-antibody that had bound itself to the surface receptor of a nerve cell. This discovery shows the mechanism behind neurological autoimmune illnesses and may be useful in the development of novel therapies for autoimmune diseases. Autoimmune illnesses are disorders that cause an individual’s immune system to mistakenly attack their body. These illnesses reduce the body’s ability to fight germs such as viruses and bacteria, which in turn, makes individuals susceptible to infections. Common autoimmune illnesses include systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis,…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Odyssey Health, Inc. (ODYY), Determined to Introduce the Market’s First FDA Approved Concussion Treatment Drug

Study Highlights Concerns on Police Involvement in Emergency Mental Health Transfers

Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study

Researchers Have Found a New, Fatal Pediatric Subtype of Cancer

Successful Early Testing of Concussion Therapy Drives Optimism for Odyssey Health, Inc. (ODYY) as Next-stage Trials are Readied

Loss of Y Chromosomes in Older Men Elevates Heart Disease Risk, Study Finds

Study Reveals Proteins That Can Trigger Immune System Malfunction

Odyssey Health, Inc. (ODYY) Responds to Growing Concerns About Concussion Head Injuries with Drug Device in Clinical Trial

Study Highlights New Insights on Neurological Autoimmune Illnesses

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search